NEW YORK (GenomeWeb News) – Illumina's second-quarter revenues retreated 2 percent year over year, but beat the consensus Wall Street estimate, the company reported after the close of the market on Tuesday.

For the three months ended July 1, the San Diego firm had revenues of $280.6 million, compared to $287.5 million a year ago, and above analyst estimates of $278.7 million. Product revenues slid to $258.8 million from $269.9 million a year ago, while service and other revenues rose to $21.8 million from $17.6 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.